Acrobiosystems Co Ltd
SZSE:301080
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Acrobiosystems Co Ltd
PP&E Net
Acrobiosystems Co Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Acrobiosystems Co Ltd
SZSE:301080
|
PP&E Net
¥502.3m
|
CAGR 3-Years
71%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
PP&E Net
¥11.5B
|
CAGR 3-Years
42%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
PP&E Net
¥5.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
PP&E Net
¥3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
PP&E Net
¥4.2B
|
CAGR 3-Years
25%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
PP&E Net
¥700.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Acrobiosystems Co Ltd
Glance View
ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
See Also
What is Acrobiosystems Co Ltd's PP&E Net?
PP&E Net
502.3m
CNY
Based on the financial report for Dec 31, 2024, Acrobiosystems Co Ltd's PP&E Net amounts to 502.3m CNY.
What is Acrobiosystems Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
91%
Over the last year, the PP&E Net growth was 20%. The average annual PP&E Net growth rates for Acrobiosystems Co Ltd have been 71% over the past three years , 91% over the past five years .
